U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07826533) titled 'Intravenous Papaverine for Term Prelabor Rupture of Membranes' on Sept. 07.
Brief Summary: This randomized, double-blind, placebo-controlled trial evaluates whether intravenous papaverine, administered as an adjunct to oxytocin, shortens the time to delivery in women with term premature rupture of membranes (PROM). Participants are randomized in a 1:1 ratio to receive either intravenous papaverine 80 mg in 100 mL of 0.9% saline or 100 mL of 0.9% saline as placebo, administered one hour after initiation of oxytocin. The primary outcome is the interval from study infusion to delivery. Secondary outcomes include mode of delivery and m...